“The project is unfreezed. Specification of design solution is underway. Since the bio-technologies take place there, they are constantly being upgraded,” Ignatyev said.
“At present, we have hired Western European experts in industrial bio-technologies, who recommended that we reconsider the project in favour of the more modern solutions,” he added.
R-Farm announced construction of a plant in Turkey in 2013. At that time, the company was planning to invest in it 100 million euro over the course of 4 – 5 years. Later, the project was suspended due to the tensions in Russian-Turkish relations.
R-Farm is a Russian pharmaceutical company, which has over 60 subsidiaries in Russia, CIS countries, the USA, Germany, Japan, Turkey and India. In 2015, the company’s sales turnover amounted to 68,7 bln roubles.